secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001651308-22-000038
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene CMO Hematology Jane Huang resigns; consulting agreement through Nov 2022
--------------------------------------------------------------------------------

- Jane Huang, M.D., CMO Hematology, resigned effective April 3, 2022.
- Consulting agreement runs from April 3 to November 14, 2022.
- Unvested options/RSUs continue vesting until June 30, 2022; exercise period extended to 90 days after consulting ends.
- No immediate replacement for CMO Hematology announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000038/0001651308-22-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130822000038/bgne-20220302.htm
  HTML page:      https://secwatch.observer/filing/0001651308-22-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer